Cardiac rhabdomyoma is a benign lesion of predominantly hamartomatous nature, composed of cardiac muscle cells with abnormalities of growth and intracellular content. It is the cardiac tumor most characteristic of fetal life and early childhood and often presents as one or more masses within the ventricular myocardium, potentially protruding into the chambers. Its natural history includes frequent spontaneous regression, especially after birth, but its location may make it clinically significant before such regression occurs. Obstruction, myocardial dysfunction and arrhythmias are the main mechanisms of injury.
The association with tuberous sclerosis complex, abbreviated TSC, is central to diagnosis. The cardiac finding may precede neurological, cutaneous or renal manifestations and offer the first opportunity to identify a multisystem disorder. Assessment must therefore proceed along two parallel lines: establishing the immediate cardiovascular risk and identifying any underlying genetic condition.
The percentages reported in case series depend on age, prenatal or postnatal case selection, and the duration of assessment for TSC manifestations. Multiple lesions greatly increase the likelihood of this association: in the multicenter study by Tworetzky and colleagues, among 94 patients with cardiac tumors diagnosed during fetal or neonatal life, tuberous sclerosis was present in 68 and in 61 of the 64 patients with multiple lesions. These findings come from referral centers and do not establish a universal probability for every echocardiographic finding, but they demonstrate the clinical significance of the number of masses.
Even a solitary lesion warrants attention and a careful search for other nodules, which may be less conspicuous. Diagnosis in adulthood is rarer and may involve persistent residual lesions or delayed recognition. Cardiac rhabdomyoma must be distinguished from extracardiac rhabdomyomas and rhabdomyosarcoma: the similarity of their names does not imply the same biology or a usual progression to malignancy.
In TSC, pathogenesis involves the TSC1 and TSC2 genes, which encode hamartin and tuberin, respectively. The protein complex containing these molecules helps regulate cell growth by controlling the RHEB–mTORC1 pathway. Loss of function decreases inhibition of anabolic signaling, increasing protein synthesis and cell growth. In the heart, this environment favors the development of nodules composed of altered cardiomyocytes embedded within their tissue of origin.
Tuberous sclerosis is an autosomal dominant disorder with variable expressivity; many cases arise from de novo variants, and a negative family history does not exclude it. Mosaic forms can occur, in which the variant is present in only some cells and may escape detection by conventional blood testing. Clinical severity cannot be inferred from the number of cardiac tumors alone: the distribution of lesions in other organs and neurological development require separate assessments.
Genotype–phenotype correlations have been documented at the group level, but the gene involved does not permit a reliable prediction of an individual course. Molecular findings should therefore be accompanied by genetic counseling, especially when obtained during pregnancy.
Some rhabdomyomas are initially regarded as isolated. This designation may reflect a true absence of other manifestations or simply an early stage of observation, before TSC becomes recognizable. An extracardiac diagnosis may emerge during follow-up. In cases without syndromic confirmation, lesion biology remains under investigation, and a TSC1 or TSC2 variant should not automatically be attributed without evidence. Conversely, the absence of a genetic finding does not turn a typical mass into a malignant lesion.
Spontaneous regression distinguishes rhabdomyoma from many other heart tumors. Decreased cell size, degenerative processes and remodeling contribute to involution, although the details governing the behavior of individual nodules are not fully understood. A phase of growth during gestation may be followed by postnatal regression; some masses regress only partially and remain visible for years. This course explains the value of observation but does not justify waiting in the presence of significant hemodynamic or electrical compromise.
The masses are usually well circumscribed and may be multiple, distributed within the interventricular septum and ventricular walls. Protrusion into a chamber changes their relationship with valves and outflow tracts; atrial and other locations are less common. Histological examination reveals large cells with vacuolated cytoplasm rich in glycogen, in which thin cytoplasmic strands may connect the nucleus to the cell periphery. These cells, traditionally called spider cells, are a characteristic finding in the appropriate morphological context.
The lesion is embedded in muscle tissue and normally lacks the friable surface of an emboligenic pedunculated tumor. Histological confirmation is obtained when surgery is needed, but typical clinical and echocardiographic findings can provide a sufficiently reliable diagnosis without tissue sampling.
Mechanical risk depends on location. A nodule near the right ventricular outflow tract may restrict pulmonary blood flow; a mass in the left ventricular outflow tract may impair systemic output. Interference with an atrioventricular valve may obstruct inflow or cause regurgitation. Numerous or large intramural nodules may decrease chamber space and alter contractility and compliance. An absolute measurement therefore has limited meaning without considering heart size and the anatomical site involved.
In the fetus, obstruction and dysfunction may increase venous pressure and cause effusions or hydrops. The fetal circulation has communications and pathways that can partly compensate for certain obstructions; after birth, falling pulmonary vascular resistance and closure of the ductus arteriosus alter this balance. A lesion that is relatively well tolerated in utero may therefore become more consequential during the first hours or days of life. Delivery planning must account for this transition rather than just the latest tumor measurement.
Electrical injury includes tachyarrhythmias and conduction disturbances. A mass near the atrioventricular junction may contribute to abnormal connections and pre-excitation, with possible reentrant tachycardias; other locations may promote ectopic activity or ventricular arrhythmias. Involvement of the septum and conduction tissues may instead cause block. Small nodules do not exclude arrhythmic risk when their location is critical.
The relationship between size and electrical effects is less straightforward than that between volume and physical obstruction. Shrinkage of a mass may be accompanied by improved rhythm, but echocardiographic follow-up does not replace electrocardiographic surveillance when pre-excitation, tachycardia or conduction abnormalities are present.
Prenatal detection often occurs during the fetal anomaly scan or an examination requested because of family history, arrhythmia or other fetal abnormalities. Lesions become more readily identifiable in the second half of pregnancy; a normal early scan does not guarantee that nodules will not become visible later. Maternal and family history should investigate TSC, epilepsy, characteristic skin lesions, renal tumors and other compatible manifestations, rather than merely asking whether a genetic diagnosis has already been established.
The fetus may remain stable or develop arrhythmia, obstructed flow, ventricular dysfunction or signs of congestion. Interpretation requires following the course over time: mass growth, emergence of regurgitation and changes in flow may be more informative than a single observation. Prenatal diagnosis allows the place of delivery and neonatal care to be organized, but cannot alone reliably predict the future neurological severity of TSC.
In the newborn and infant, many rhabdomyomas remain asymptomatic. When they cause clinical effects, tachypnea, feeding difficulties, sweating, poor growth, cyanosis, pallor or episodes of reduced responsiveness may occur. Arrhythmias may present as persistent tachycardia, intermittent episodes or bradycardia. Low cardiac output may be accompanied by cold extremities and reduced urine output, while critical obstruction may become apparent during the postnatal circulatory transition.
Older children may experience palpitations, reduced exercise capacity, presyncope or syncope. Distinguishing an arrhythmic episode from a neurological manifestation is particularly important in patients with TSC, in whom both problems may coexist.
The postnatal history covers the course of pregnancy, documentation of the masses, any fetal arrhythmias, adaptation to birth and treatments already given. Family history and extracardiac manifestations are assessed, including skin lesions, episodes suspicious for seizures and known renal abnormalities. Echocardiographic regression of a nodule must not interrupt syndromic evaluation when relevant clues remain: the cardiac tumor and systemic disease follow different trajectories.
The physical examination assesses heart rate and rhythm, oxygen saturation, blood pressure, pulses, peripheral perfusion and work of breathing. Murmurs, hepatomegaly and signs of congestion may accompany obstruction or dysfunction, but normal auscultation does not exclude intramyocardial nodules. Assessment of growth and feeding is part of the infant’s functional examination. The skin, mucous membranes and nervous system are examined during the TSC workup; absence of obvious skin findings at birth does not exclude the disorder.
Fetal echocardiography is the main prenatal investigation. The most characteristic finding is a homogeneously echogenic, often multiple mass embedded in ventricular myocardium or the septum and sometimes protruding into the lumen. The examination documents the number, size and location of lesions and searches all chambers for additional nodules. It must also assess inflow, outflow, ventricular function, regurgitation, effusions and signs of impaired venous return. Rhythm is assessed using echocardiographic techniques that distinguish atrial from ventricular activity.
Serial measurements must be interpreted relative to fetal heart growth and blood flow. An increase in diameter does not necessarily mean hemodynamic deterioration, while a stable nodule may become more problematic if its relationship with a valve changes or an arrhythmia develops.
After birth, transthoracic echocardiography confirms lesion distribution and documents the new circulatory state. Doppler assessment quantifies obstruction and regurgitation, while ventricular examination establishes systolic function, chamber dimensions and effects on filling. Reduced flow may influence the magnitude of the measured gradient: a relatively modest velocity does not always exclude a serious problem if cardiac output is impaired. Apparently normal structures must also be examined to distinguish a mass from prominent trabeculations or papillary muscles.
An electrocardiogram is needed to identify pre-excitation, conduction disturbances and arrhythmias present at the time of recording. Telemetry and ambulatory monitoring are used according to clinical stability and episode frequency. In patients with intermittent symptoms, a single normal recording may be insufficient. Documenting the arrhythmic mechanism guides treatment and allows assessment of whether anatomical regression is accompanied by electrical improvement.
Cardiac magnetic resonance imaging is reserved mainly for solitary or atypical masses, unclear anatomical relationships or questions unresolved by echocardiography. It may show a lesion with signal intensity close to myocardium on T1-weighted sequences and relatively higher signal on T2-weighted sequences, with generally less pronounced enhancement than a fibroma. These findings are suggestive and vary with composition, size and technique. In young children, the need for sedation and the examination’s actual contribution to decision-making must also be considered.
CT is selectively indicated when details unavailable by other methods are required, accounting for radiation and contrast agents. Diagnostic catheterization and biopsy are not part of the routine pathway for a typical presentation.
The main differential diagnosis among intramural masses is cardiac fibroma, which is often solitary, collagen-rich and lacks the usual tendency to regress. Magnetic resonance characterization may help, but lesion number and signal features are not absolute rules. Teratomas more often have pericardial relationships and complex structure, whereas vascular lesions may show different perfusion and imaging characteristics. In a newborn with catheters or other predisposing factors, an intracavitary thrombus must also be considered, especially when its attachment and clinical context do not correspond to a myocardial nodule.
Unexpected growth, marked heterogeneity, destructive infiltration or discordant findings warrant reconsideration of the diagnosis. Malignant neoplasms are rare in this age group, but the designation rhabdomyoma must not be applied to every echogenic mass. In classic cases, by contrast, multiple intramyocardial lesions, the TSC context and their course may make invasive confirmation unnecessary. Histological diagnosis remains the reference standard when tissue is available, without becoming a requirement that obliges surgery in a stable child.
Cardiac rhabdomyoma is a major criterion in the international TSC criteria updated in 2021. A definite clinical diagnosis requires two major criteria or one major and at least two minor criteria, according to the combinations specified by the consensus. Multiple rhabdomyomas still constitute only one category of criterion, not two different major criteria. A cardiac finding alone may therefore support a possible diagnosis and necessitate a search for other manifestations.
Genetically, identification of a constitutional pathogenic variant in TSC1 or TSC2 is diagnostic in the appropriate context. A variant of uncertain significance does not carry the same weight; a negative conventional test does not exclude TSC, partly because mosaicism or variants undetected by the method may be present.
Genetic counseling clarifies the significance of the finding, reconstructs the family history and coordinates any investigations in parents and at-risk relatives. During pregnancy, decisions about prenatal testing and its interpretation require a dedicated pathway. A molecular diagnosis may establish the presence of the disorder but cannot precisely predict the severity of all future manifestations. It is important to distinguish this prognostic limitation from the test’s ability to establish etiology.
Neurological assessment includes the recommended investigations to detect cortical tubers, subependymal nodules and other lesions, using brain MRI when appropriate. In infants, electroencephalography and surveillance for suspicious episodes are relevant even before overt clinical epilepsy. Early detection of neurological and neurodevelopmental problems is part of TSC care, regardless of the need to treat the cardiac mass.
When indicated, fetal MRI may contribute to identifying prenatal cerebral manifestations, but a study without recognizable abnormalities does not exclude all subsequent expressions of the disorder.
Investigation of renal, cutaneous and ocular manifestations is coordinated according to age and recommendations: appropriate renal imaging, blood pressure and kidney function assessment, dermatological examination and ophthalmological evaluation are all part of care. Testing is not determined by rhabdomyoma size but by suspected or confirmed TSC. In apparently isolated cases, repeated assessment over time takes account of emerging signs. This is not metastatic staging, because rhabdomyoma does not behave as a disseminating tumor.
Cardiac risk stratification integrates critical location, severity of obstruction, function, arrhythmias and serial course. For the fetus, signs of hydrops, gestational age and availability of care at delivery are additional considerations; for the newborn, circulatory adaptation and need for support. This evaluation determines whether observation is safe, whether drug therapy can act within a useful time frame or an immediate solution is required. The prospect of future regression does not eliminate the need to protect current cardiac function.
For stable patients without significant obstruction and with a well-tolerated rhythm, observation is often the preferred approach. Serial follow-up documents regression or persistence and allows prompt recognition of functional changes. Systematic removal of asymptomatic nodules would impose unjustified risks in a population in which involution is common. Visit frequency is tailored to clinical stage: a fetus with growing masses and a child with small stable remnants do not require the same schedule.
Delivery planning considers the risk of neonatal instability. Cases with significant obstruction, arrhythmias or impaired function require access to pediatric cardiology, intensive care and cardiac surgery according to anticipated needs. The presence of a rhabdomyoma alone does not automatically mandate premature delivery or cesarean section; timing and mode depend on the maternal–fetal balance and obstetric circumstances. Coordination before birth may prevent delays when circulatory transition makes an obstruction more consequential.
Neonatal stabilization addresses respiratory failure, low cardiac output, congestion and arrhythmias in a specialist setting. When obstruction makes systemic or pulmonary blood flow dependent on the ductus arteriosus, maintaining ductal patency may provide temporary support while the treatment strategy is determined. This option depends on anatomy and does not apply to every rhabdomyoma. Critical conditions demand rapid decisions: spontaneous regression and the effects of growth-directed treatment are not immediate solutions for hemodynamic collapse.
Arrhythmias are treated according to mechanism, age and hemodynamic tolerance. Drug-based rhythm control may support a period of waiting for regression, whereas resistant or life-threatening forms require pediatric electrophysiology involvement and evaluation of further options. Pre-excitation must be recognized because it affects tachycardia interpretation and drug selection. Treatment of the rhythm and treatment of the mass are related but not identical: echocardiographic shrinkage does not automatically demonstrate disappearance of an arrhythmic circuit.
Surgery is considered for critical obstruction, severe functional impairment or arrhythmias that cannot be controlled with a less invasive strategy, as well as in certain diagnostic situations. The aim is to correct the mechanism threatening the patient while preserving as much myocardium and conduction tissue as possible. For multiple lesions, removing every nodule is not necessarily beneficial: treating the mass responsible for obstruction may be sufficient, leaving the others to their natural course.
Complete excision must be weighed against the risk of septal, valvular or ventricular injury. In some anatomical settings, a limited resection restoring flow is appropriate, whereas attempting oncological radicality does not have the same rationale as in a malignant tumor.
Understanding the TSC–mTOR pathway has enabled treatment directed at the growth mechanism. Everolimus and sirolimus can promote mass reduction and have been used mainly for symptomatic rhabdomyomas, lesions difficult to resect or cases associated with high surgical risk. The expected benefit is relief of an obstructed passage or functional improvement sooner than would be expected from spontaneous progression alone. A small, well-tolerated nodule is not, by itself, sufficient reason to expose a child to systemic treatment.
The 2021 review by Sugalska and colleagues collected 41 patients, mostly from case reports and small series: 33 had clinical manifestations and improvement was reported in 30. These findings support a therapeutic option but are affected by selection, preferential publication of favorable cases, heterogeneous protocols and the disease’s inherent spontaneous regression. The percentages must not be interpreted as individual probabilities derived from randomized trials.
Choosing this treatment therefore requires multidisciplinary consideration of foreseeable benefit, time available before injury occurs and medication-related risk. Demonstrated efficacy of mTOR inhibitors for other TSC manifestations does not replace evaluation of evidence specific to cardiac rhabdomyoma.
Treatment requires therapeutic drug monitoring because exposure and metabolism may vary substantially, particularly in newborns. Dose, blood concentrations and treatment duration are established by an experienced center and adjusted for response, age, interactions and toxicity. Drugs that affect metabolic and transport systems are relevant, including those used to treat infections and epilepsy. Monitoring includes complete blood counts, liver and kidney function, metabolic profile and clinical surveillance, as well as echocardiographic and rhythm assessments.
Potential adverse effects include infections, stomatitis, hematologic and metabolic changes and tolerability issues that may require modification or discontinuation. Vaccination and invasive procedures must be coordinated with immunomodulatory treatment and the individual clinical situation. No single treatment duration regimen applies to every mass. Regrowth may be observed after discontinuation, sometimes without recurrence of symptoms; follow-up must therefore assess volume together with function, not merely whether a residual lesion is present.
Prenatal administration through maternal treatment remains a highly selective approach. The 2024 review by Mustafa and colleagues included eleven fetuses treated with mTOR inhibitors, with favorable effects on size and obstruction in published cases. The small sample and absence of an adequate comparator prevent generalization regarding efficacy and safety. The 2025 review with an additional clinical observation by Muschel and colleagues also highlighted limitations and possible unfavorable outcomes even after a reduction in mass size.
Transplacental treatment requires simultaneous assessment of mother and fetus, toxicity, gestational timing and alternatives. It must be distinguished from simple surveillance of a stable fetal rhabdomyoma and discussed in centers experienced in fetal medicine, pediatric cardiology, genetics and pharmacology.
Cardiac prognosis is often favorable in patients who survive the critical period without significant injury and whose lesions regress. Regression may be complete or partial and occur over different time frames; some masses remain visible without functional consequences. The most important determinants of immediate outcome are obstruction, dysfunction, arrhythmias and fetal hydrops. The mere presence of multiple lesions does not necessarily imply a worse hemodynamic prognosis than a single mass in a critical location.
Mortality estimates from prenatal series must be interpreted in light of case selection and initial severity. Referral centers and published reports tend to include more complicated cases, while discovery of a small, well-tolerated nodule represents a different situation. The multisystem course of TSC remains an independent determinant of quality of life: a heart that has returned to normal on echocardiography does not exclude epilepsy, neurodevelopmental difficulties or future renal manifestations. Syndromic surveillance continues according to its own indications.
The 2021 international consensus recommends an echocardiogram every 1–3 years in asymptomatic pediatric patients with TSC until regression of rhabdomyomas has been documented. This guidance applies to stable surveillance rather than fetuses, newborns with significant masses or symptomatic children, who may require much closer monitoring. Follow-up intervals are also adjusted during mTOR inhibitor treatment, after discontinuation and following surgery.
For asymptomatic patients with TSC, the consensus recommends an ECG every 3–5 years to detect conduction abnormalities, with more frequent assessments or prolonged monitoring when symptoms warrant them. Known pre-excitation, previous arrhythmias, episodes of syncope and residual abnormalities require an individualized plan. Follow-up for apparently isolated rhabdomyomas is also based on course and risk, while any emerging extracardiac signs prompt renewed evaluation for TSC.
Transition to adult care must preserve records of arrhythmias, operations, genotype and original lesion locations. This information remains useful even when masses are no longer visible.
Major complications include fetal hydrops, inflow or outflow obstruction, heart failure and severe impairment of cardiac output. Right-sided obstruction may reduce pulmonary blood flow, while left-sided obstruction may compromise systemic perfusion. Sustained arrhythmias can rapidly worsen function even when a mass does not directly obstruct the lumen. In the most severe cases, fetal or neonatal death is possible; urgency depends on the functional mechanism, not histological benignity.
Rhythm disturbances may persist or recur despite a reduction in mass size. Conduction blocks and tachyarrhythmias therefore require dedicated assessment, especially following surgery or a period of instability. Rhabdomyoma is not usually a friable source of emboli and does not require anticoagulation simply because it is present. A thrombotic or embolic event warrants investigation of associated conditions and definition of a specific indication, particularly in newborns undergoing procedures and catheterization.
Surgical complications depend on location and include myocardial injury, valvular damage, residual defects and injury to the conduction system. Drug-related complications include toxicity and infections during mTOR inhibition, while regrowth after discontinuation may necessitate a new treatment decision. The possibility of spontaneous regression makes proportional treatment essential: the best outcome is to maintain safe function and rhythm while the lesion evolves, integrating this care with management of the genetic disorder when present.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.